Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MONETTE: Ceralasertib Monotherapy vs Ceralasertib plus Durvalumab in PD-(L)1–Resistant Advanced Melanoma
2021-001722-21Phase 2Active
- Sponsor
- AstraZeneca
- Start
- Sep 2021
- Modality
- PD-1/PD-L1 Inhibitors → Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in cutaneous melanoma (CM) comparing Ceralasertib monotherapy with Ceralasertib plus Durvalumab (2 arms). Primary endpoint: Objective response rate (ORR). Started Sep 2021; status: active.
02
Drugs
ceralasertibdurvalumab
03
Conditions
cutaneous melanoma (CM)
Beyond the preview
Go deeper on 2021-001722-21.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-001722-21.